# Carmen Blanco-Aparicio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3951435/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 66 papers | 4,312 citations | 147801 31 h-index | 110387 64 g-index |
| 70 all docs | 70 docs citations | 70 times ranked | 7382 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications. Current Cancer Drug Targets, 2008, 8, 187-198. | 1.6 | 685 |
| 2 | Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science, 2016, 354, . | 12.6 | 466 |
| 3 | PTEN, more than the AKT pathway. Carcinogenesis, 2007, 28, 1379-1386. | 2.8 | 355 |
| 4 | STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nature Medicine, 2018, 24, 1024-1035. | 30.7 | 285 |
| 5 | Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis, 2015, 36, S254-S296. | 2.8 | 239 |
| 6 | The PIM Family of Serine/Threonine Kinases in Cancer. Medicinal Research Reviews, 2014, 34, 136-159. | 10.5 | 191 |
| 7 | A Novel Regulatory Mechanism of Map Kinases Activation and Nuclear Translocation Mediated by Pka and the Ptp-Sl Tyrosine Phosphatase. Journal of Cell Biology, 1999, 147, 1129-1136. | 5.2 | 152 |
| 8 | Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities. Biochemical Pharmacology, 2013, 85, 629-643. | 4.4 | 137 |
| 9 | Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agents. Biochemical Journal, 2003, 372, 193-201. | 3.7 | 112 |
| 10 | PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood, 2011, 118, 5517-5527. | 1.4 | 83 |
| 11 | Potato Carboxypeptidase Inhibitor, a T-knot Protein, Is an Epidermal Growth Factor Antagonist That Inhibits Tumor Cell Growth. Journal of Biological Chemistry, 1998, 273, 12370-12377. | 3.4 | 78 |
| 12 | Lysosomal trapping of palbociclib and its functional implications. Oncogene, 2019, 38, 3886-3902. | 5.9 | 57 |
| 13 | MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis, 2007, 28, 2096-2104. | 2.8 | 55 |
| 14 | Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Letters, 2011, 300, 145-153. | 7.2 | 53 |
| 15 | Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in Glioblastoma Mouse Models and Patient-Derived Xenografts. Cancer Cell, 2017, 32, 590-607.e4. | 16.8 | 52 |
| 16 | MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis, 2007, 28, 1646-1652. | 2.8 | 48 |
| 17 | Activation of Phosphatidylinositol 3-Kinase by Membrane Localization of p110Î± Predisposes Mammary Glands to Neoplastic Transformation. Cancer Research, 2008, 68, 9643-9653. | 0.9 | 47 |
| 18 | Modulation of telomere protection by the PI3K/AKT pathway. Nature Communications, 2017, 8, 1278. | 12.8 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Therapeutic inhibition of <scp>TRF</scp> 1 impairs the growth of p53 â€deficient Kâ€Ras <sup> G12V </sup> â€ induced lung cancer by induction of telomeric <scp>DNA</scp> damage. EMBO Molecular Medicine, 2015, 7, 930-949. | 6.9 | 45 |
| 20 | Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis, 2007, 28, 584-594. | 2.8 | 44 |
| 21 | The mTOR pathway is necessary for survival of mice with short telomeres. Nature Communications, 2020, 11, 1168. | 12.8 | 44 |
| 22 | A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Research, 2014, 16, 482. | 5.0 | 41 |
| 23 | Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. Cell Cycle, 2011, 10, 2751-2762. | 2.6 | 40 |
| 24 | Extreme sensitivity to YondelisÂ® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. Journal of Cellular Biochemistry, 2007, 100, 339-348. | 2.6 | 39 |
| 25 | Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1591-1597. | 2.2 | 38 |
| 26 | Multiple cancer pathways regulate telomereÂprotection. EMBO Molecular Medicine, 2019, 11, e10292. | 6.9 | 36 |
| 27 | Global hyperactivation of enhancers stabilizes human and mouse naive pluripotency through inhibition of CDK8/19 Mediator kinases. Nature Cell Biology, 2020, 22, 1223-1238. | 10.3 | 35 |
| 28 | The essential role of PIM kinases in sarcoma growth and bone invasion. Carcinogenesis, 2012, 33, 1479-1486. | 2.8 | 34 |
| 29 | Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. Haematologica, 2013, 98, 57-64. | 3.5 | 33 |
| 30 | Disruptive chemicals, senescence and immortality. Carcinogenesis, 2015, 36, S19-S37. | 2.8 | 32 |
| 31 | Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies. Clinical Cancer Research, 2018, 24, 3550-3559. | 7.0 | 32 |
| 32 | Levels of p27kip1 determine Aplidin sensitivity. Molecular Cancer Therapeutics, 2007, 6, 1310-1316. | 4.1 | 31 |
| 33 | Spinophilin loss contributes to tumorigenesis in vivo. Cell Cycle, 2011, 10, 1948-1955. | 2.6 | 31 |
| 34 | Mechanism of action of potato carboxypeptidase inhibitor (PCI) as an EGF blocker. Cancer Letters, 2005, 226, 169-184. | 7.2 | 30 |
| 35 | Inhibiting PI3K as a therapeutic strategy against cancer. Clinical and Translational Oncology, 2009, 11, 572-579. | 2.4 | 28 |
| 36 | Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models. PLoS ONE, 2010, 5, e9305. | 2.5 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Conditional Transgenic Expression of PIM1 Kinase in Prostate Induces Inflammation-Dependent Neoplasia. PLoS ONE, 2013, 8, e60277. | 2.5 | 28 |
| 38 | The role of PIM1/PIM2 kinases in tumors of the male reproductive system. Scientific Reports, 2016, 6, 38079. | 3.3 | 28 |
| 39 | The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Nature Communications, 2019, 10, 5428. | 12.8 | 28 |
| 40 | Two Clusters of Residues at the Docking Groove of Mitogen-activated Protein Kinases Differentially Mediate Their Functional Interaction with the Tyrosine Phosphatases PTP-SL and STEP. Journal of Biological Chemistry, 2002, 277, 2629-2636. | 3.4 | 27 |
| 41 | Antiâ€tumor effects of PIM / PI 3K/ mTOR triple kinase inhibitor IBL â€302 in neuroblastoma. EMBO Molecular Medicine, 2019, 11, e10058. | 6.9 | 27 |
| 42 | Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate. Carcinogenesis, 2007, 28, 1418-1425. | 2.8 | 25 |
| 43 | Non-genotoxic activation of p53 through the RPL11-dependent ribosomal stress pathway. Carcinogenesis, 2014, 35, 2822-2830. | 2.8 | 25 |
| 44 | Genetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and Carcinogens. Frontiers in Oncology, 2014, 4, 109. | 2.8 | 25 |
| 45 | Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus. Oncotarget, 2017, 8, 58872-58886. | 1.8 | 24 |
| 46 | ERK2 Shows a Restrictive and Locally Selective Mechanism of Recognition by Its Tyrosine Phosphatase Inactivators Not Shared by Its Activator MEK1. Journal of Biological Chemistry, 2005, 280, 37885-37894. | 3.4 | 22 |
| 47 | Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Oncogene, 2020, 39, 3028-3040. | 5.9 | 22 |
| 48 | Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors. European Journal of Medicinal Chemistry, 2019, 168, 87-109. | 5.5 | 21 |
| 49 | Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria. Anti-Cancer Drugs, 2005, 16, 977-987. | 1.4 | 20 |
| 50 | Downâ€regulation of spinophilin in lung tumours contributes to tumourigenesis. Journal of Pathology, 2011, 225, 73-82. | 4.5 | 20 |
| 51 | Genetic modelling of the PTEN/AKT pathway in cancer research. Clinical and Translational Oncology, 2008, 10, 618-627. | 2.4 | 19 |
| 52 | Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5208-5214. | 2.2 | 19 |
| 53 | PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases. PLoS ONE, 2014, 9, e112148. | 2.5 | 18 |
| 54 | Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24415-24426. | 7.1 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | ETP-46321, a dual p110Î±/Î´ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. Biochemical Pharmacology, 2016, 106, 56-69. | 4.4 | 14 |
| 56 | A clinically compatible drugâ€screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. EMBO Molecular Medicine, 2022, 14, e14552. | 6.9 | 12 |
| 57 | Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis. BMC Cancer, 2014, 14, 281. | 2.6 | 11 |
| 58 | Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 1485-1493. | 3.6 | 11 |
| 59 | Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors. European Journal of Medicinal Chemistry, 2021, 211, 113109. | 5.5 | 8 |
| 60 | Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 1794-1801. | 2.8 | 8 |
| 61 | Pyrido[2,3-b][1,5]benzoxazepin-5(6H)-one derivatives as CDK8 inhibitors. European Journal of Medicinal Chemistry, 2020, 201, 112443. | 5.5 | 7 |
| 62 | Induction of Lysosome Membrane Permeabilization as a Therapeutic Strategy to Target Pancreatic Cancer Stem Cells. Cancers, 2020, 12, 1790. | 3.7 | 7 |
| 63 | Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC. Cancers, 2021, 13, 2139. | 3.7 | 6 |
| 64 | Identification of novel PI3K inhibitors through a scaffold hopping strategy. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4794-4799. | 2.2 | 5 |
| 65 | Regulation of MAPK Cascades by Protein Tyrosine Phosphatases. , 2004, 250, 103-112. | | 4 |
| 66 | Screening protocol for the identification of modulators by immunofluorescent cellâ€based assay. Chemical Biology and Drug Design, 2020, 95, 66-78. | 3.2 | 0 |